Synlogic Public Company

Primary contact

Synlogic is dedicated to bringing innovative medicines to patients by driving the convergence of two revolutionary fields: synthetic biology and the microbiome. Using its synthetic biotics platform, the company is engineering probiotic bacteria to perform specific therapeutic functions with established links to disease. Synlogic can deliver these synthetic biotics orally, where they act from the gut microbiome to correct missing or dysfunctional metabolic activities throughout the body. It also aims to deliver synthetic biotics at the site of disease in cases where local activity is critical, as in stimulation of immune effectors to combat certain tumors. Synlogic can rapidly translate this groundbreaking science and technology into medicines that have the potential to change the lives of patients. Its lead programs target patients with rare genetic metabolic diseases, including urea cycle disorders (UCD) and phenylketonuria (PKU). It is also hard at work on synthetic biotics to address more prevalent conditions, including inflammatory bowel disease (IBD), cancer, and metabolic conditions such as diabetes and obesity.
Primary contact

Funding 💰

Total $116.4M
Select investors Atlas Venture, New Enterprise Associates, Bill & Melinda Gates Foundation, OrbiMed, Deerfield Management, CLI Ventures, Ally Bridge Group
Last update: May 14, 2018